Cachexia - Pipeline Insight, 2025

This “Cachexia - Pipeline Insight, 2025” report provides comprehensive insights about 27+ companies and 27+ pipeline drugs in Cachexia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Cachexia: Understanding

Cachexia: Overview

Cachexia or wasting syndrome is a complicated metabolic syndrome related to underlying illness and characterized by muscle mass loss with or without fat mass loss that is often associated with anorexia, an inflammatory process, insulin resistance, and increased protein turnover. This specific ailment was described as a syndrome of irreversible muscle wasting, extreme weight loss and loss of body fat in the terminally ill patients in the late stages of serious diseases like cancer, HIV or AIDS, COPD, kidney disease, and congestive heart failure (CHF).

This specific ailment is so destructive that it taps into other sources of energy, namely skeletal muscle and adipose tissue when the body senses a lack of nutrition. Furthermore, the Nutritional status is compromised in direct response to tumor-induced alterations in the metabolism. Cachexia adversely affects the patient’s ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. As a result of all these negative effects, the body begins to waste away. Generally the reduction of Hormonal anabolic mediators such as growth hormone, insulin-like growth factor-1 (IGF-1), testosterone, and ghrelin are also being observed among the Cachexia affected individuals. “Cachexia - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cachexia pipeline landscape is provided which includes the disease overview and Cachexia treatment guidelines. The assessment part of the report embraces, in depth Cachexia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cachexia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cachexia R&D. The therapies under development are focused on novel approaches to treat/improve Cachexia.

Cachexia Emerging Drugs Chapters

This segment of the Cachexia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cachexia Emerging Drugs

Espindolol: Actimed Therapeutics

ACM-001 (S-pindolol) - previously known as MT-102 - is a lead candidate of Actimed therapeutics and is chemically-related to a well-established beta-blocker for hypertension and angina (pindolol). S-pindolol (ACM-001) is an anabolic/catabolic transforming agent with a multifunctional effect on three key pharmacological targets relevant for cancer cachexia:

• β-1receptor antagonism that blocks catabolism
• Increased anabolism and muscle growth, through partial β2 receptor agonism
• Central 5-HT1A antagonism that can stimulate appetite and thereby improve overall patient outcomes as well as improving fatigue

It has been observed in nonclinical models that, firstly, S-pindolol reduces catabolism via non-selective β-blockade. Secondly, it increases anabolism via partial β2-agonism8. Finally, it helps reduce fatigue and increase appetite via central 5-HT1A activity9. The ability of ACTAs to act on several elements of the disease causality, and thereby directly address the causes of cancer cachexia via multiple routes, potentially makes lead candidate S-pindolol and the broader class unique among the products currently in development. A Phase II/III clinical development programme is in planning to confirm and expand upon the positive results demonstrated in a proof of concept Phase IIa trial, ACT-ONE.

GCBWB204: Green Cross Wellbeing

GCBWB204 (BST-204) is a novel drug candidate for cancer cachexia, which is a nutritional imbalance in cancer patients that causes muscular atrophy and metabolic disorders. Using GC Wellbeing’s exclusive Bio-Transformation Technology, BST204, which has increased the amount of special saponin components by a small margin, has therapeutic effects on decreased muscle mass and exercise capacity caused by cancer cachexia and increased inflammation and hematopoietic toxicity. BST204 has been tested for safety in Canadian non-clinical toxicity studies and European clinical studies. GCBWB204 has multimodal functions of suppressing muscle disintegration and inflammatory cytokines, while triggering muscle growth. Green Cross Wellbeing has patent protection for pharmaceutical composition and manufacturing method of GCWB 204 in South Korea. The company has currently completed the phase II clinical trial of GCWB204 on non-small cell lung cancer and digestive cancer patients in Europe.

AV-380: AVEO Oncology

AVEO’s AV-380, is a preclinical first-in-class potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), is a pro-inflammatory cytokine whose elevated circulating levels have been correlated with cachexia in cachectic cancer patients and several animal models of cancer cachexia. The evidence suggests that a pro-inflammatory state may be responsible for many of the symptoms associated with cachexia, a complex metabolic syndrome characterized by malnutrition and severe involuntary weight loss due to the loss of muscle and fat tissue, as well as the clinical manifestation of anemia, inflammation and suppression of immune functions.

The company has cited preclinical data showing that inhibition of GDF15 results in a switch from catabolism to anabolism - a finding that according to the company suggests that GDF15 inhibition with AV-380 may reverse the effects of cachexia, which affects some 5 million Americans with advanced cancer and other chronic diseases. The Company has recently regained the rights to its AV-380 program for the potential treatment of cachexia and is considering a variety of options to advance the program’s development. The company is working to initiate preclinical toxicology studies mid-2019 to support the potential filing of an investigational new drug application with the FDA.

Cachexia: Therapeutic Assessment

This segment of the report provides insights about the different Cachexia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cachexia

There are approx. 27+ key companies which are developing the therapies for Cachexia. The companies which have their Cachexia drug candidates in the most advanced stage, i.e. Phase II include, Actimed Therapeutics.

Phases

The report covers around 27+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Cachexia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cachexia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cachexia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cachexia drugs.

Cachexia Report Insights

• Cachexia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Cachexia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Cachexia drugs?
• How many Cachexia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cachexia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Cachexia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Cachexia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tvardi Therapeutics
• TMS Co. Ltd
• RaQualia Pharma
• Pfizer
• Pephexia Therapeutics
• Oncocross
• NGM Biopharmaceuticals
• MGC Pharmaceuticals
• Keros Therapeutics
• Incyte Corporation
• ImmunoForge
• Immuneering Corporation
• Green Cross Wellbeing
• GlaxoSmithKline
• Faraday Pharmaceuticals
• Extend Biosciences
• Energenesis Biomedica
• Endevica Bio
• CNBX Pharmaceuticals
• CatalYm
• Caelus Health
• AVEO Oncology
• Artelo Biosciences
• Aphios Corporation
• AliveGen
• AEterna Zentaris
• Actimed Therapeutics
• AAVogen

Key Products

• TTI 101
• TMS-008
• RQ-00433412
• PF 06946860
• Research programme: peptide-based pharmacotherapies
• OC514
• NGM120
• Tetrinol
• Research programme: ligand traps
• Ruxolitinib
• PF-1801
• Research Programme (Cancer Cachexia)
• GCBWB204
• GSK2881078
• ACM-002
• EXT418
• EOM613
• ENERGI-F704
• TCMCB07
• Cannabics capsules
• CTL-002
• CH-0701
• AV-380
• ART27.13
• APH-0802
• Research programme: novel Biotherapeutics

This product will be delivered within 1-3 business days.